Acidosis D000138

Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » Acid-Base Imbalance » Acidosis

Description

A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (4)

Acidosis, Lactic
21 drugs (16 approved, 5 experimental)

Acidosis, Renal Tubular
6 drugs (4 approved, 2 experimental)

Acidosis, Respiratory
2 approved drugs

Ketosis
16 drugs (7 approved, 9 experimental)


Approved Indicated Drugs (3)

lactic acid

sodium bicarbonate

tromethamine (tham)

Phase 3 Indicated Drugs (4)

ringer's lactate

sodium chloride

Veverimer

zirconium silicate (Lokelma)

Phase 2 Indicated Drugs (4)

meglumine

potassium chloride (klor-con)

potassium citrate (urocit-k)

spirulina platensis

Phase 1 Indicated Drugs (1)

netazepide

Other Experimental Indicated Drugs (1)

propofol (diprivan)


Organization Involved with Phase 4 Indications (11)

Club des Jeunes Néphrologues

Emory University

Mayo Clinic

Ontario HIV Treatment Network

Queen's University, Belfast

Sanofi

The Cleveland Clinic

University of Minnesota

University of Ulsan

University of Vienna

University of Zurich

Organization Involved with Phase 3 Indications (16)

Advicenne Pharma

Azienda Sanitaria ASL Avellino 2

Case Western Reserve University

CIHR Canadian HIV Trials Network

CTI Clinical Trial and Consulting Services

GlaxoSmithKline

King Abdul-Aziz University

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institutes of Health (NIH)

Tricida, Inc.

University of British Columbia

University of Florida

University of Glasgow

University of Montpellier

Vanderbilt University

Yeshiva University

Organization Involved with Phase 2 Indications (22)

Children's National Medical Center

Children's National Research Institute

Columbia University

Harvard University

Icahn School of Medicine at Mount Sinai

Mallinckrodt

Moderna Therapeutics

National Heart, Lung, and Blood Institute (NHLBI)

Sangart

Santhera

Stanford University

Swiss Federal Institute of Technology

The University of Texas, Dallas

University of Alabama, Birmingham

University of California, Los Angeles

University of California, San Diego

University of Colorado

University of Colorado, Denver

University of London

University of Padova

University of Pennsylvania

University of Pittsburgh

Organization Involved with Phase 1 Indications (2)

University of Rochester

University of Utah

Organization Involved with Other Experimental Indications (21)

Central South University

Chattanooga-Hamilton County Hospital Authority

DLR German Aerospace Center

Erasmus University Rotterdam

Government of Taiwan

Hebrew University

Humboldt University

Makerere University

McMaster University

National Taiwan University

Novo Nordisk

Rush University

Shahid Beheshti University of Medical Sciences

State University of New York

State University of New York, Buffalo

Tel Aviv University

Universitaetsklinikum Schleswig-Holstein

University of Cambridge

University of Erlangen-Nuremberg

University of Maryland

University of Texas at Houston

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.